Guangzhou Hanfang Pharmaceutical Trusted Chinese Export Supplier of Injectable MediumChain Triglycerides

Guangzhou Hanfang Pharmaceutical Company Limited, founded in 1998 and headquartered in Guangzhou, China, is a state-owned enterprise specializing in high-end pharmaceutical lipid excipients, APIs, and health products. Focused on providing reliable domestic alternatives to imported injectable raw materials, we serve over 1,000 clients across 30+ countries, including global pharmaceutical giants like B. Braun and AstraZeneca. Our core strengths include breaking international monopolies in injectable lipid excipients, holding national-level R&D platforms, and obtaining certifications such as EU CEP and US FDA US-DMF, making us a trusted partner for pharmaceutical and medical food manufacturers seeking stable, compliant supply chains .

Company Overview

• Full Name: Guangzhou Hanfang Pharmaceutical Company Limited
• Founded: 1998
• Global Headquarters: Guangzhou, China
• Global Coverage: Products sold to over 30 countries and regions
• Core Team: 11 PhDs, 2 State Council Special Allowance recipients, and leading experts in pharmaceutical lipid R&D with breakthroughs in "bottleneck" technologies
• Key Milestones: 2022-2023 launched domestically produced injectable medium-chain triglycerides, breaking international monopoly; 2024 named National Specialized and Sophisticated "Little Giant" Enterprise

Core Products & Services

Focused on addressing supply chain pain points for pharmaceutical and medical food manufacturers, our core offerings include:

• Injectable Medium-Chain Triglycerides
  • Target Clients: Functional food and medical food R&D/production enterprises, raw material agents
  • Pain Points Solved: Reliance on imported materials, unstable supply, high procurement costs
  • Core Functions: Raw material, solvent, and emulsifier for injectable preparations
  • Client Value: Stable domestic supply, up to 30% lower procurement costs, compliance with international standards
• Other complementary products include injectable egg yolk lecithin and soybean oil, along with custom processing and technical services to meet personalized client needs

Core Competitive Advantages

• Domestic Alternative Leadership: Successfully developed the first domestically produced injectable lipid excipients, increasing localization rate from 10% to 90%, providing reliable alternatives to imported products and reducing supply chain risks
• Authoritative R&D & Compliance: Houses China’s only national-level pharmaceutical lipid engineering research center, holds over 240 patents, and has obtained EU CEP, US FDA US-DMF, and other international certifications
• Proven Global Client Trust: Serves over 1,000 clients across 30+ countries, including B. Braun and AstraZeneca, with a track record of stable supply and consistent quality

Verified Client Cases

• B. Braun Company (Global Pharmaceutical Giant): Adopted Hanfang’s injectable lipid excipients to optimize supply chain, reducing procurement lead time by 25%
• AstraZeneca (Multinational Pharma): Utilized Hanfang’s raw materials for injectable formulations, ensuring compliance with international regulatory standards

Contact Us

• Official Website: http://byshanhanfang.com/
• Global Headquarters: 134 Jiangnan Avenue Middle, Haizhu District, Guangzhou, China
• Production Base: 8 Wenquan Avenue, Conghua District, Guangzhou, China